Skip to main content
SpringerLink
Log in

Is the P388 murine tumor no longer adequate as a drug discovery model?

  • Preclinical Review
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frei E: The national cancer chemotherapy program. Science 217:600–606, 1982.

    Google Scholar 

  2. Goldin A, Schepartz SA, Venditti JM, De Vita VT, Jr: Historical development and current strategy of the National Cancer Institute drug development program. In: De Vita Jr VT, Busch H (eds) Methods in Cancer Research XVI. Academic Press, New York, NY, 1979, pp 165–245.

    Google Scholar 

  3. Staquet MJ, Byar DP, Green SB, Rozencweig M: Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. Cancer Treat Rep 67:753–765, 1983

    Google Scholar 

  4. Venditti JM, Wesley RA, Plowman J: Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976–1982, and future directions. In: Garattini S, Goldin A, Hawking F (eds) Advances in Pharmacology and Chemotherapy, Vol 20. Academic Press, Orlando FL, 1984, pp 1–20.

    Google Scholar 

  5. Venditti JM: Preclinical drug development: rationale and methods. Seminars in Oncology 8:349–361, 1981

    Google Scholar 

  6. Zubrod CG: Chemical control of cancer. Proc Nat Acad Sci USA 69:1042–2047, 1972

    Google Scholar 

  7. Goldin A, Venditti JM, MacDonald JS, Muggia FM, Henney JE, De Vita VT, Jr: Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Europ J Cancer 17:129–142, 1981

    Google Scholar 

  8. Frei E: Curative cancer chemotherapy. Cancer Res 45:6523–6537, 1985

    Google Scholar 

  9. Hirschberg E: Patterns of response of animal tumors to anticancer agents: a systematic analysis of the literature in experimental cancer chemotherapy — 1945–1958. Cancer Res 23:521–1084, 1963

    Google Scholar 

  10. Skipper H: Drug evaluation in experimental tumor systems: potential and limitations in 1961. Cancer Chemother Rep 16:11–19, 1962

    Google Scholar 

  11. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold Jr DP, Schabel Jr FM: Induction and chemotherapeutics response of two transplantable ductal adenocarcinomas of the pancreas in C57B1/6 mice. Cancer Res 45:717–726, 1984

    Google Scholar 

  12. Schabel Jr FM, Skipper HE, Trader MW, Laster WR, Griswold Jr DP, Corbett TH: Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67:905–922, 1983

    Google Scholar 

  13. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcino mas. Cancer 40:2660–2680, 1977

    Google Scholar 

  14. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 62:1471–1499, 1978

    Google Scholar 

  15. Venditti JM: The National Cancer Institute antitumor drug discovery program, current and future perspectives: a com mentary. Cancer Treat Rep 67:767–772, 1983

    Google Scholar 

  16. Leiter J, Abbott BJ, Bourke AR, Schepartz SA, Wodinsky. Screening data from the cancer chemotherapy national service center screening laboratories. XIV. Cancer Res 23:1278–1473, 1963

    Google Scholar 

  17. Venditti JM: Relevance of transplantable animal-tumor systems to the selection of new agents for clinical trial. In: Pharmacological Basis of Cancer Chemotherapy. Williams and Wilkins Co, 1975, pp 245–270

  18. Goldin A, Serpick AA, Mantel N: Experimental screening procedures and clinical predictability value. Cancer Chemother Rep 50:173–218, 1966

    Google Scholar 

  19. Griswold DP, Laster Jr WR, Snow MY, Schabel Jr FM, Skipper HE: Experimental evaluation of potential anti cancer agents. XII. Quantitative drug response of the SA180, CA755, and leukemia L1210 systems to a “standard list” of “active” and “inactive” agents. Cancer Res 23: 271–521, 1963

    Google Scholar 

  20. Skipper HE, Wilcox WS, Schabel Jr FM, Laster Jr WR, Mattil L: Experimental evaluation of potential anticancer agents. X. A specific test for distinguishing false positives. Cancer Chemother Rep 29:1–62, 1963

    Google Scholar 

  21. Pitot HC, Shires TK, Moyer G, Garret CT: Phenotypic variability as a manifestation of translational control. In: Busch H (ed) The Molecular Biology of Cancer. Academic Press Inc, London Ltd, 1974, pp 523–533

  22. Corbett TH, Griswold Jr DP, Roberts BJ, Peckham JC, Schabel Jr FM: Tumor induction relationships in develop ment of transplantable cancers of the colon in mice for che motherapy assays, with a note on carcinogen structure. Cancer Res 35:2434–2439, 1975

    Google Scholar 

  23. Corbett TH, Griswold Jr DP, Roberts BJ, Schabel Jr FM: Cytotoxic adjuvant therapy and the experimental model, Chapter 10. In: Stoll BA (ed) New Aspects of Breast Cancer, Vol. 4, Systemic Control of Breast Cancer. William Heinemann Medical Books Ltd, London, 1981, pp 204–243

    Google Scholar 

  24. Harris H: Gene action and differentiation; malignancy. In: Cell Fusion. Harvard University Press, Cambridge MA, 1970, pp 57–59

    Google Scholar 

  25. Ephrussi B: Applications of cell hybridization to the study of cancer. In: Hybridization of Somatic Cells. Princeton University Press, Princeton NJ, 1972, pp 99–109

    Google Scholar 

  26. Harris H, Klein G: Malignancy of somatic cell hybrids. Nature 224:1315–1316, 1969

    Google Scholar 

  27. Hill DL, Montgomery JA: Selective uptake and retention of anticancer agents by sensitive cells. Cancer Chemother Phar macol 4:221, 1980

    Google Scholar 

  28. Mintz B, Fleishman RA: Teratocarcinomas and other neoplasms as developmental defects in gene expression. Adv in Cancer Res 34:211–278, 1981

    Google Scholar 

  29. Johnson RD, Golden A: The clinical impact of screening and other experimental tumor studies. Cancer Treat Rev 2:1, 1975

    Google Scholar 

  30. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD: Flavone acetic acid (NSC 347512), a novel agent with preclinical antitumor activity against the colon adenocarcinoma 38 in mice. Cancer Treat Rep, 70: 631–635, 1986

    Google Scholar 

  31. Corbett TH, Bissery M, Wozniak A, Plowman J, Polin L, Tapazoglou E, Dieckman J, Valeriote F: Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs, 4:207–220, 1986

    Google Scholar 

  32. Shoemaker RH, Wolpert DeFilippes MK, Kern DH, Lieber MM, Makuch RW, Melnick NR, Miller WT, Salmon SE, Simon RM, Venditti JM, Von Hoff DD: Application of a human tumor colony forming assay to new drug screening. Cancer Res 45:2145–2153, 1985

    Google Scholar 

  33. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold Jr DP, Schabel Jr FM: Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42: 1701–1715, 1982

    Google Scholar 

  34. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ: Cell culture screen, KB Protocol. 1,600. Cancer Chemother Rep 3:17, 1972

    Google Scholar 

  35. Shoemaker RH, Abbott BJ, MacDonald MM, Mayo JG, Venditti JM, Wolpert DeFilippes MK: Use of the KB cell line for in vitro cytotoxicity assays. Cancer Treat Rep 67:97, 1983

    Google Scholar 

  36. Schabel Jr FM: Laboratory methods for the detection and development of clinically useful anticancer drugs. In: Burchenal JH, Oettgen HF (eds) Cancer: Achievements, Chal lenges and Prospects for the 1980's. Vol 2. Grune and Stratton Inc, New York, 1981, pp 11–32

    Google Scholar 

  37. Corbett TH: A selective soft agar assay for drug discovery. Proc Am Assoc for Cancer Res 25:325, 1984

    Google Scholar 

  38. Corbett TH, Wozniak A, Gerpheide S, Hanka L: A selec tive two-tumor soft agar assay for drug discovery. In: In vitro and In vivo Models for Detection of New Antitumor Drugs; 14th International Congress of Chemotherapy. Hanka LJ, Kondo T, White RJ (eds) Univ of Tokyo Press, 1986, pp 5–14

  39. Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: Kallman RF (ed) The Use of Rodent Tumors in Experimental Cancer Therapy. Pergamon Press, 1987, in press

  40. Shoemaker RH: New approaches to antitumor drug screening: the human tumor-colony-formation assay. Cancer Treat Rep 70:9–12, 1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wayne State University School of Medicine, P.O. Box 02188, 48201, Detroit, MI, USA

    Thomas H. Corbett, Frederick A. Valeriote & Laurence H. Baker

Authors
  1. Thomas H. Corbett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick A. Valeriote
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence H. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The first draft of this “position paper” was included in the Minutes of an NCI Workshop: “Disease Oriented Antitumor Drug Discovery”, January 9–10, 1985. We have updated the original text to include new findings and a brief description of NCI drug-screening changes either implemented or planned since the workshop.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corbett, T.H., Valeriote, F.A. & Baker, L.H. Is the P388 murine tumor no longer adequate as a drug discovery model?. Invest New Drugs 5, 3–20 (1987). https://doi.org/10.1007/BF00217664

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00217664

Key words

Search

Navigation